Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Respistim
- Development stage
- Unknown
- Lead developer
- Natstim
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Peptides
- Administration
- Oral
01
Overview
Respistim is an immune-supporting dietary supplement developed by Muno-Vax, a health and wellness company based in Bulgaria. It is formulated as a complex containing Respivax, a polybacterial immunomodulator composed of killed bacterial lysates, alongside a blend of vitamins (A, C, D, E, and B-complex), minerals (manganese, copper, selenium), and antioxidants. The product is intended to enhance the body's natural defenses against respiratory infections, particularly during the autumn and winter seasons. It is marketed for adults and children over 9 years of age to reduce the frequency and severity of cold and flu symptoms. As a nutritional supplement, it is designed for long-term use during the cold season to support both non-specific and specific immune responses.
- Brand names
- Respistim
Beyond the preview
Go deeper on Respistim.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Respistim.